Critical issues in drug and biomarker development and standardisation of assays

Bookmark and Share
Published: 7 Jan 2021
Views: 83
Dr Reena Philips - US Food and Drug Administration (FDA)

Dr Reena Phillips speaks to ecancer about the critical issues in drug and biomarker development from IBCD 2020.

She initially lists all the problems being faced by the industry and academia in terms of biomarker based drug and testing kit development and then moves on to explain the steps through which these issues can be resolved.

She also highlights what important changes we can be looking for in the future with regard to this topic.

Dr Phillips also gives her opinion about the current issue of non-standardised assay policies leading to imprecision medicine and winds up the interview by highlighting what has been done so far to standardise assays/testing kits.